All Posts:immunotherapy
-
New Understanding of How to Harness the Immune System to Fight Cancer
Georgetown University’s Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, which are infection and tumor-fighting white blood cells, so that they have a superior memory, thereby making them more effective in killing cancer cells.
Category: News Release
-
Clinical Study Deepens Understanding of Mesothelioma and Opens the Door to Potential Treatment Options
People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.
Category: News Release
-
Celebrating ‘Thrivership’
Survivors of melanoma and kidney cancer gathered to celebrate “thrivership” during a luncheon that might not have been possible as recently as 10 years ago as people with these types of cancer are living longer and experiencing cures.
Category: Lombardi Stories
-
Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?
For the first time, new research by Georgetown scientists shows potential to make immunotherapy effective in pancreatic cancer by combining it with a drug that makes cancer cells more responsive to immunotherapy. The research is now in a phase 2 clinical trial being tested in human patients.
Category: Lombardi Stories
-
Understanding Immunotherapy Resistance Leads to New Therapeutic Strategies — and Hope
Samir Khleif, MD, an immunologist and professor of oncology at Georgetown Lombardi, is working to understand why some cancers become resistant to immunotherapy, and how that resistance can be overcome.
Category: Lombardi Stories
-
Atkins Inducted as Academy of Immuno-Oncology Fellow
The Society for Immunotherapy of Cancer (SITC) has inducted Georgetown Lombardi Deputy Director Michael B. Atkins, MD, as a Fellow of the Academy of Immuno-Oncology (FAIO). The 2023 class was inducted November 3 at the SITC’s 38th Annual Meeting in San Diego.
Category: Lombardi Stories
-
New Study Finds Personalized mRNA Vaccine Given with Immunotherapy Reduces Recurrence in High-Risk Melanoma Patients
A new study conducted by an international team of researchers, including clinical investigators at Georgetown University’s Lombardi Comprehensive Cancer Center, demonstrates that a personalized cancer mRNA vaccine combined with immunotherapy reduces recurrence and improves survival for people with advanced melanoma.
Category: Lombardi Stories
-
Key Studies Conducted at Georgetown Lombardi Lead to Better Treatment for People With Melanoma
(March 1, 2023) — Results from a pair of clinical trials published in recent months have changed the treatment landscape for people with advanced melanoma, offering a clearer path for improved survival. The studies, conducted at Georgetown University’s Lombardi Comprehensive Cancer Center and other cancer centers around the country, explored the best treatment options and […]
Category: Lombardi Stories
-
The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology
MILWAUKEE (October 6, 2022)— No uniform method has been established to predict the probability of success for individual clinical trials. To help identify clinical trials with a high likelihood of offering benefit to patients, the Society for Immunotherapy of Cancer (SITC) brought together a team of experts in immuno-oncology to create a conceptual framework for […]
Category: News Release
-
Advanced Melanoma Survival Improves Significantly When Immunotherapy is Given Before Targeted Therapy
The findings, coupled with results from another recent clinical trial, mark significant advances in the treatment of melanoma. WASHINGTON (September 27, 2022) — A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received […]
Category: News Release